Qiagen's DxS scores deal with Pfizer for brain tumour assay
This article was originally published in Clinica
Executive Summary
Qiagen's recently-acquired subsidiary, DxS, has struck a deal with drugs giant Pfizer for a companion diagnostic test kit that will be used alongside a new brain tumour drug.